retatrutide mechanism triple agonist glp-1 gip glucagon receptor A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology PDB-101: Molecule of the Month:

When someone first starts treatment with a GLP-1 receptor agonist, we slowly introduce the medication for a reason theres a risk of gastrointestinal side effects as your body gets used to the drug

The business insights provided exceeded our expectations and we were extremely impressed

Biological actions of GLP-1, source: reference [1] Evolution of GLP1 GLP-1RAs Currently, there are nine GLP-1RAs approved for marketing worldwide (Table 1), mainly for the treatment of diabetes and obesity, of which tirzepatide is a novel dual GLP-1RA/GIPR agonist

Bile acids are known to be ligands of the nuclear farnesoid X receptor (FXR) and Takeda G protein-coupled receptor 5 (TGR5), also known as G-protein-coupled bile acid receptor 1 (GPBAR1)

J Endocr Soc

Lower blood pressure and BW loss correlate independently with SGLT2 inhibitor treatment, with the effect of both GLP-1RA and SGLT2 inhibitors being significantly greater on systolic BP than on diastolic BP [4]